Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00643747Phase 1Completed

Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

Role: collaborator

NCT00482027Phase 1Completed

Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine

Role: collaborator

NCT00888446Phase 2Completed

Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid

Role: collaborator

NCT00126724Phase 1Completed

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

Role: lead

NCT00617032Phase 1Completed

Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

Role: lead

NCT00073463Phase 2Terminated

Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis

Role: lead

All 6 trials loaded